-DOCSTART- -X- O
Esophageal -X- _ O
malignancy -X- _ O
is -X- _ O
a -X- _ O
disease -X- _ O
with -X- _ O
poor -X- _ O
prognosis. -X- _ O
Curative -X- _ O
therapy -X- _ O
incorporates -X- _ O
surgery -X- _ O
and -X- _ O
is -X- _ O
burdensome -X- _ O
with -X- _ O
high -X- _ O
rates -X- _ O
of -X- _ O
infection -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
The -X- _ O
role -X- _ O
of -X- _ O
yeast -X- _ O
as -X- _ O
causative -X- _ O
organisms -X- _ O
of -X- _ O
post-esophagectomy -X- _ B-Patient
infections -X- _ O
is -X- _ O
poorly -X- _ O
defined. -X- _ O
Consequently -X- _ O
, -X- _ O
the -X- _ O
benefits -X- _ O
of -X- _ O
specific -X- _ O
antifungal -X- _ O
prophylactic -X- _ O
therapy -X- _ O
in -X- _ O
improving -X- _ O
patient -X- _ O
outcome -X- _ O
are -X- _ O
unclear. -X- _ O
Therefore -X- _ O
, -X- _ O
this -X- _ O
study -X- _ O
aimed -X- _ O
at -X- _ O
investigating -X- _ O
the -X- _ O
incidence -X- _ B-Outcome
of -X- _ I-Outcome
yeast -X- _ I-Outcome
infections -X- _ I-Outcome
at -X- _ O
the -X- _ O
University -X- _ O
Medical -X- _ O
Center -X- _ O
Groningen -X- _ O
among -X- _ O
565 -X- _ B-Patient
post-esophagectomy -X- _ I-Patient
patients -X- _ I-Patient
between -X- _ O
1991 -X- _ O
and -X- _ O
2017. -X- _ O
The -X- _ O
results -X- _ O
show -X- _ O
that -X- _ O
7.3 -X- _ B-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
patients -X- _ I-Outcome
developed -X- _ I-Outcome
a -X- _ I-Outcome
yeast -X- _ I-Outcome
infection -X- _ I-Outcome
after -X- _ I-Outcome
esophageal -X- _ I-Outcome
resection -X- _ I-Outcome
with -X- _ I-Outcome
significantly -X- _ I-Outcome
increased -X- _ I-Outcome
incidence -X- _ I-Outcome
among -X- _ I-Outcome
patients -X- _ I-Outcome
suffering -X- _ I-Outcome
from -X- _ I-Outcome
diabetes -X- _ I-Outcome
mellitus. -X- _ I-Outcome
For -X- _ O
patients -X- _ O
with -X- _ O
yeast -X- _ O
infections -X- _ O
, -X- _ O
higher -X- _ B-Outcome
Acute -X- _ I-Outcome
Physiology -X- _ I-Outcome
and -X- _ I-Outcome
Chronic -X- _ I-Outcome
Health -X- _ I-Outcome
Evaluation -X- _ I-Outcome
( -X- _ I-Outcome
APACHE -X- _ I-Outcome
) -X- _ I-Outcome
II -X- _ I-Outcome
scores -X- _ I-Outcome
, -X- _ I-Outcome
more -X- _ I-Outcome
frequent -X- _ I-Outcome
intensive -X- _ I-Outcome
care -X- _ I-Outcome
unit -X- _ I-Outcome
readmissions -X- _ I-Outcome
, -X- _ I-Outcome
prolonged -X- _ I-Outcome
hospital -X- _ I-Outcome
stays -X- _ I-Outcome
and -X- _ I-Outcome
higher -X- _ I-Outcome
mortality -X- _ I-Outcome
rates -X- _ I-Outcome
were -X- _ I-Outcome
observed. -X- _ I-Outcome
One-year -X- _ I-Outcome
survival -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
lower -X- _ I-Outcome
for -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
yeast -X- _ I-Outcome
infection -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
diabetes -X- _ I-Outcome
mellitus -X- _ I-Outcome
and -X- _ I-Outcome
yeast-positive -X- _ I-Outcome
pleural -X- _ I-Outcome
effusion. -X- _ I-Outcome
We -X- _ O
conclude -X- _ O
that -X- _ O
the -X- _ O
incidence -X- _ B-Outcome
of -X- _ I-Outcome
yeast -X- _ I-Outcome
infections -X- _ I-Outcome
following -X- _ I-Outcome
esophagectomy -X- _ I-Outcome
is -X- _ I-Outcome
considerable -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
diabetes -X- _ I-Outcome
mellitus -X- _ I-Outcome
are -X- _ I-Outcome
at -X- _ I-Outcome
increased -X- _ I-Outcome
risk. -X- _ I-Outcome
Furthermore -X- _ O
, -X- _ O
yeast -X- _ B-Outcome
infections -X- _ I-Outcome
are -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
higher -X- _ I-Outcome
complication -X- _ I-Outcome
rates -X- _ I-Outcome
and -X- _ I-Outcome
mortality. -X- _ I-Outcome
These -X- _ O
observations -X- _ O
encourage -X- _ O
further -X- _ O
prospective -X- _ O
investigations -X- _ O
on -X- _ O
the -X- _ O
possible -X- _ O
benefits -X- _ O
of -X- _ O
antifungal -X- _ O
prophylactic -X- _ O
therapy -X- _ O
for -X- _ O
esophagectomy -X- _ O
patients -X- _ O
. -X- _ O

